Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Abstract As of May 1, 2017, 74 antibody-based molecules have been approved by a
regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based …

In vitro display technologies, best exemplified by phage and yeast display, were first
described for the selection of antibodies some 20 years ago. Since then, many antibodies …

Antibodies constitute the most rapidly growing class of human therapeutics and the second
largest class of drugs after vaccines. The generation of potent antibody therapeutics, which I …

We describe evidence for a novel mechanism of monoclonal antibody (MAb)–directed
nanoparticle (immunoliposome) targeting to solid tumors in vivo. Long-circulating …

Filamentous bacteriophage, long and thin filaments that are secreted from the host cells
without killing them, have been an antithesis to the standard view of head-and-tail bacterial …

A quarter of a century after their advent, monoclonal antibodies have become the most
rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases …

Engineered antibodies now represent over 30% of biopharmaceuticals in clinical trials, as
highlighted by recent approvals from the US Food and Drug Administration. Recombinant …

Nanomedicines have significant potential for cancer treatment. Although the majority of
nanomedicines currently tested in clinical trials utilize simple, biocompatible liposome …

Antibody or ligand-mediated targeting of liposomal anticancer drugs to antigens expressed
selectively or over-expressed on tumor cells is increasingly being recognized as an effective …